Literature DB >> 7710931

Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.

C Courage1, J Budworth, A Gescher.   

Abstract

Inhibitors of protein kinase C (PKC) such as the staurosporine analogues UCN-01 and CGP 41251 possess antineoplastic properties, but the mechanism of their cytostatic action is not understood. We tested the hypothesis that the ability of these compounds to arrest growth is intrinsically linked with their propensity to inhibit PKC. Compounds with varying degrees of potency and specificity for PKC were investigated in A549 and MCF-7 carcinoma cells. When the log values of drug concentration which arrested cell growth by 50% (IC50) were plotted against the logs of the IC50 values for inhibition of cytosolic PKC activity, two groups of compound could be distinguished. The group which comprised the more potent inhibitors of enzyme activity (calphostin C, staurosporine and its analogues UCN-01, RO 31-8220, CGP 41251) were the stronger growth inhibitors, whereas the weaker enzyme inhibitors (trimethylsphingosine, miltefosine, NPC-15437, H-7, H-7I) affected proliferation less potently. GF 109203X was exceptional in that it inhibited PKC with an IC50 in the 10(-8) M range, yet was only weakly cytostatic. To substantiate the role of PKC in the growth inhibition caused by these agents, cells were depleted of PKC by incubation with bryostatin 1 (1 microM). The susceptibility of these enzyme-depleted cells towards growth arrest induced by staurosporine, RO 31-8220, UCN-01 or H-7 was studied. The drug concentrations which inhibited incorporation of [3H]thymidine into PKC-depleted A549 cells by 50% were slightly, but not significantly, lower than significantly, lower than those observed in control cells. These results suggest that PKC is unlikely to play a direct role in the arrest of the growth of A549 and MCF-7 cells mediated by these agents. Staurosporine is not only a strong inhibitor of PKC but also mimics activators of this enzyme in that it elicits the cellular redistribution of certain PKC isoenzymes. The ability of kinase inhibitors other than staurosporine to exert a similar effect was investigated. Calphostin C, H-7, H-7I, miltefosine, staurosporine, UCN-01, RO 31-8220, CGP 41251 or GF 109203X were incubated for 30 min with A549 cells in the absence or presence of the PKC activator 12-O-tetradecanoyl phorbol-13-acetate. The subcellular distribution of PKC-alpha-, -epsilon and -zeta was measured by Western blot analysis. None of the agents affected PKC-alpha or -zeta.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710931      PMCID: PMC2033742          DOI: 10.1038/bjc.1995.137

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

Review 1.  Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

2.  Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity.

Authors:  P D Davis; L H Elliott; W Harris; C H Hill; S A Hurst; E Keech; M K Kumar; G Lawton; J S Nixon; S E Wilkinson
Journal:  J Med Chem       Date:  1992-03-20       Impact factor: 7.446

3.  Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases.

Authors:  D M Gadbois; J R Hamaguchi; R A Swank; E M Bradbury
Journal:  Biochem Biophys Res Commun       Date:  1992-04-15       Impact factor: 3.575

4.  Modulation by staurosporine of phorbol-ester-induced effects on growth and protein kinase C localization in A549 human lung-carcinoma cells.

Authors:  T D Bradshaw; A Gescher; G R Pettit
Journal:  Int J Cancer       Date:  1992-04-22       Impact factor: 7.396

5.  Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.

Authors:  G Martiny-Baron; M G Kazanietz; H Mischak; P M Blumberg; G Kochs; H Hug; D Marmé; C Schächtele
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

6.  The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts.

Authors:  A M Cacace; S N Guadagno; R S Krauss; D Fabbro; I B Weinstein
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

7.  Protein kinase C: a novel target for inhibiting gastric cancer cell invasion.

Authors:  G K Schwartz; J Jiang; D Kelsen; A P Albino
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity.

Authors:  H Mischak; J A Goodnight; W Kolch; G Martiny-Baron; C Schaechtle; M G Kazanietz; P M Blumberg; J H Pierce; J F Mushinski
Journal:  J Biol Chem       Date:  1993-03-25       Impact factor: 5.157

9.  Selective redistribution of protein kinase C isozymes by thapsigargin and staurosporine.

Authors:  S C Kiley; P J Parker; D Fabbro; S Jaken
Journal:  Carcinogenesis       Date:  1992-11       Impact factor: 4.944

10.  A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

Authors:  J Prendiville; D Crowther; N Thatcher; P J Woll; B W Fox; A McGown; N Testa; P Stern; R McDermott; M Potter
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

View more
  8 in total

1.  UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

Authors:  A Monks; E D Harris; A Vaigro-Wolff; C D Hose; J W Connelly; E A Sausville
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

2.  The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.

Authors:  Fei Yan; Na Shen; Jiuxia Pang; Julian R Molina; Ping Yang; Shujun Liu
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

3.  Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells.

Authors:  Matthias Felber; Jürgen Sonnemann; James F Beck
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

4.  Staurosporines disrupt phosphatidylserine trafficking and mislocalize Ras proteins.

Authors:  Kwang-jin Cho; Jin-Hee Park; Andrew M Piggott; Angela A Salim; Alemaheyu A Gorfe; Robert G Parton; Robert J Capon; Ernest Lacey; John F Hancock
Journal:  J Biol Chem       Date:  2012-11-02       Impact factor: 5.157

5.  Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cells.

Authors:  L M Osorio; M Rottenberg; M Jondal; S C Chow
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

6.  Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells.

Authors:  C Courage; R Snowden; A Gescher
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

7.  Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.

Authors:  J Budworth; R Davies; J Malkhandi; T W Gant; D R Ferry; A Gescher
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

8.  ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays.

Authors:  Camilo Guzmán; Manish Bagga; Amanpreet Kaur; Jukka Westermarck; Daniel Abankwa
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.